Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Cut to $60.00 by Analysts at Barclays

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price decreased by Barclays from $62.00 to $60.00 in a report released on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday. Guggenheim reiterated a “buy” rating and issued a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, The Goldman Sachs Group increased their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $61.33.

Tarsus Pharmaceuticals Trading Up 2.1 %

Tarsus Pharmaceuticals stock opened at $44.48 on Wednesday. The company has a 50 day moving average price of $50.97 and a 200 day moving average price of $43.13. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -11.67 and a beta of 1.01.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. Research analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $25,000. GF Fund Management CO. LTD. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $44,000. R Squared Ltd bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $53,000. FMR LLC raised its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after purchasing an additional 3,537 shares in the last quarter. Finally, Quarry LP bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $166,000. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.